ReviewTzu chi medical journal
Use of disease-specific biomarkers in identifying interstitial cystitis and guiding effective treatment for its different subtypes.
Review in Tzu chi medical journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a heterogeneous condition with unidentifiable causes and unknown pathophysiology. Exploring potential biomarkers with high reliability might predict IC/BPS subtypes and guide specific treatment to achieve successful outcomes. The currently used clinical biomarkers to identify IC/BPS include pain symptoms, low bladder capacity, bladder wall thickness, and serum or urinary parameters. The wide application of serum biomarkers for identifying IC/BPS from patients with similar bladder symptoms is not established yet due to their low specificity. Patients with IC/BPS exhibit distinct urinary inflammatory cytokine profiles and oxidative stress biomarkers compared with controls, and the urine levels of biomarkers were correlated with pathologic conditions of the bladder. Identifying IC/BPS subtypes, including Hunner's IC (HIC) and non-Hunner's IC (NHIC) with different cystoscopic characteristics, can facilitate specific treatments with satisfactory outcomes. Using a cluster of biomarkers has been reported to aid in the detection of IC/BPS patients, and patients with HIC can be recognized from patients with IC/BPS. Machine learning using the decision tree model can further provide high accuracy for predicting treatment outcomes. Currently, a satisfactory disease biomarker that can be used to identify IC/BPS subtypes and guide appropriate bladder therapy is lacking. In the future, the treatment goal may be achieved by combining noninvasive clinical parameters with cluster of urinary biomarkers and constructing nomograms for identifying IC/BPS in patients with lower urinary tract symptoms and discriminating patients with HIC from those with IC/BPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.